The Burden of Carbapenem-Resistant
Acinetobacter baumannii
Acinetobacter infections
COVID-19
SARS-CoV-2
antimicrobial drug resistance
carbapenems
critical care
intensive care unit
multidrug resistance
nosocomial infections
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
11
07
2022
revised:
26
08
2022
accepted:
26
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Since the beginning of the COVID-19 pandemic, the impact of superinfections in intensive care units (ICUs) has progressively increased, especially carbapenem-resistant Acinetobacter baumannii (CR-Ab). This observational, multicenter, retrospective study was designed to investigate the characteristics of COVID-19 ICU patients developing CR-Ab colonization/infection during an ICU stay and evaluate mortality risk factors in a regional ICU network. A total of 913 COVID-19 patients were admitted to the participating ICUs; 19% became positive for CR-Ab, either colonization or infection (n = 176). The ICU mortality rate in CR-Ab patients was 64.7%. On average, patients developed colonization or infection within 10 ± 8.4 days from ICU admission. Scores of SAPS II and SOFA were significantly higher in the deceased patients (43.8 ± 13.5, p = 0.006 and 9.5 ± 3.6, p < 0.001, respectively). The mortality rate was significantly higher in patients with extracorporeal membrane oxygenation (12; 7%, p = 0.03), septic shock (61; 35%, p < 0.001), and in elders (66 ± 10, p < 0.001). Among the 176 patients, 129 (73%) had invasive infection with CR-Ab: 105 (60.7%) Ventilator-Associated Pneumonia (VAP), and 46 (26.6%) Bloodstream Infections (BSIs). In 22 cases (6.5%), VAP was associated with concomitant BSI. Colonization was reported in 165 patients (93.7%). Mortality was significantly higher in patients with VAP (p = 0.009). Colonized patients who did not develop invasive infections had a higher survival rate (p < 0.001). Being colonized by CR-Ab was associated with a higher risk of developing invasive infections (p < 0.001). In a multivariate analysis, risk factors significantly associated with mortality were age (OR = 1.070; 95% CI (1.028−1.115) p = 0.001) and CR-Ab colonization (OR = 5.463 IC95% 1.572−18.988, p = 0.008). Constant infection-control measures are necessary to stop the spread of A. baumannii in the hospital environment, especially at this time of the SARS-CoV-2 pandemic, with active surveillance cultures and the efficient performance of a multidisciplinary team.
Identifiants
pubmed: 36079137
pii: jcm11175208
doi: 10.3390/jcm11175208
pmc: PMC9456723
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2021 May 18;72(10):e533-e541
pubmed: 32820807
J Clin Microbiol. 2016 Mar;54(3):593-612
pubmed: 26699703
J Glob Antimicrob Resist. 2021 Mar;24:136-147
pubmed: 32889142
J Clin Microbiol. 1998 Jul;36(7):1938-41
pubmed: 9650940
Crit Care Med. 2014 May;42(5):1081-8
pubmed: 24394630
Med Intensiva. 2017 Nov;41(8):497-499
pubmed: 28081920
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):1999-2006
pubmed: 27287765
Virulence. 2012 May 1;3(3):243-50
pubmed: 22546906
Crit Care. 2021 Aug 31;25(1):317
pubmed: 34461962
J Infect Dev Ctries. 2021 Jan 31;15(1):58-68
pubmed: 33571146
J Infect. 2019 Aug;79(2):130-138
pubmed: 31145911
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
J Med Microbiol. 2020 Jul;69(7):949-959
pubmed: 32584215
Infect Control Hosp Epidemiol. 2022 Jun;43(6):815-817
pubmed: 33685542
Infect Control Hosp Epidemiol. 2022 Apr;43(4):461-466
pubmed: 33858547
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Membranes (Basel). 2021 Apr 30;11(5):
pubmed: 33946566
PLoS One. 2021 Mar 25;16(3):e0249038
pubmed: 33765049
Intensive Care Med. 2015 Dec;41(12):2057-75
pubmed: 26438224
Intensive Care Med. 2018 Dec;44(12):2216-2218
pubmed: 29797028
J Med Virol. 2021 Jul;93(7):4564-4569
pubmed: 33822390
BMC Infect Dis. 2018 Jan 5;18(1):11
pubmed: 29304746
Clin Microbiol Infect. 2020 Jul;26(7):808-810
pubmed: 32360446
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
Eur J Clin Microbiol Infect Dis. 2017 May;36(5):797-805
pubmed: 28000030
J Glob Antimicrob Resist. 2020 Dec;23:398-400
pubmed: 33242674
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Curr Opin Infect Dis. 2019 Feb;32(1):69-76
pubmed: 30520737
Pathogens. 2021 Aug 10;10(8):
pubmed: 34451470
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Infect Prev Pract. 2021 Mar;3(1):100113
pubmed: 34316574
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Crit Care Med. 2013 Dec;41(12):2733-42
pubmed: 23982021
Crit Care Med. 2011 Apr;39(4):651-8
pubmed: 21242793
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Membranes (Basel). 2021 Aug 09;11(8):
pubmed: 34436366
Microb Drug Resist. 2021 Sep;27(9):1167-1175
pubmed: 33600262
BMC Infect Dis. 2020 Sep 1;20(1):646
pubmed: 32873235
Ann Intensive Care. 2021 Sep 15;11(1):136
pubmed: 34524562
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546093
Antimicrob Resist Infect Control. 2021 Aug 19;10(1):123
pubmed: 34412693